Immunologic Response to Combination Nucleoside Analogue plus Protease Inhibitor Therapy in Stable Antiretroviral Therapy–Experienced Human Immunodeficiency Virus–Infected Children

Open Access
Publisher Website
Google Scholar
Abstract
The response of 40 immunologic parameters was studied for 147 clinically stable, protease inhibitor-naive, human immunodeficiency virus (HIV)-infected children aged 2–17 years when antiretroviral therapy was changed to either a dual nucleoside analogue regimen or a protease inhibitor-containing regimen. Immunologie response to therapy, as measured by lymphocyte subsets, 3-color flow cytometric measures, and lymphoproliferative assays, were investigated for changes in weeks 44 and 48. The most significant changes after baseline that were associated with the administration of a protease inhibitor-containing regimen were seen for percentages of CD8+/CD38+/HLA-DR+, CD8+/CD95+/CD28−, and CD8. The percentages of CD8+/CD38+/HLA-DR+ and CD8+/CD95+/CD28− decreased from baseline medians of 33% and 46% to medians of 18% and 30% at week 44 (P < .0001 for both). Median CD4 cell count increased 168 cells/μL (from 694 cells/μL to 862 cells/μL; P = .02) by week 48 in this clinically stable population. Changes in lymphoproliferative responses to HIV antigens and recall antigens did not increase over time and between groups.

This publication has 0 references indexed in Scilit: